ARTICLE | Clinical News
Macugen regulatory update
May 31, 2004 7:00 AM UTC
The partners said FDA's Dermatologic & Ophthalmic drugs advisory committee will review on Aug. 27 the companies' NDA for Macugen to treat exudative (wet) age-related macular degeneration (AMD). In Pha...